| ID Source | ID |
|---|---|
| PubMed CID | 657720 |
| CHEMBL ID | 30953 |
| CHEBI ID | 114452 |
| Synonym |
|---|
| HMS1479A15 |
| MLS000080138 , |
| CBDIVE_009397 |
| OPREA1_247087 |
| CHEMDIV3_002127 |
| smr000034314 |
| OPREA1_147121 |
| NCGC00020639-01 |
| STK066287 |
| 1-cyclohexyl-2,3-dihydro-1h-pyrrolo[2,3-b]quinolin-4-amine |
| CHEBI:114452 |
| CHEMBL30953 |
| AKOS001642323 |
| 1-cyclohexyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-amine |
| NCGC00020639-02 |
| CCG-18234 |
| HMS2337H05 |
| cid_657720 |
| bdbm38552 |
| (1-cyclohexyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)amine |
| 1h-pyrrolo[2,3-b]quinolin-4-amine, 1-cyclohexyl-2,3-dihydro- |
| IVZOSCLDRXLTLK-UHFFFAOYSA-N |
| Q27195855 |
| Class | Description |
|---|---|
| pyrroloquinoline | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 22.3342 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 7.0795 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 19.9526 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
| ClpP | Bacillus subtilis | Potency | 14.1254 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.7329 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| 67.9K protein | Vaccinia virus | Potency | 28.1838 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| IDH1 | Homo sapiens (human) | Potency | 29.0929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 6.3096 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 40.3604 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2100; AID2242 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| geminin | Homo sapiens (human) | Potency | 16.7958 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 12.5893 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 11.2202 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 25.1189 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| short transient receptor potential channel 6 isoform 1 | Mus musculus (house mouse) | EC50 (µMol) | 70.7900 | 0.0200 | 20.5189 | 70.7900 | AID2696 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID230841 | MRP1 antagonism was determined percentage of MCF-7/VP cells surviving in the absence of vincristine/percentage of MCF-7/VP cells surviving in the presence of vincristine | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6 | Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. |
| AID231072 | Pgp antagonism was determined percentage of NCI/ADR cells surviving in the absence of vinblastine/percentage of NCI/ADR cells surviving in the presence of vinblastine | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6 | Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. |
| AID230733 | Ratio of the Pgp to that of MRP1 was determined | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6 | Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. |
| AID211666 | Toxicity was determined against of MCF-7 cells at a dose of 10 ug/mL | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6 | Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||